secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001104659-25-007028
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock appoints Lisa Wyman as CTQO; COO role eliminated, CFO search begins
--------------------------------------------------------------------------------

- Lisa Wyman appointed Chief Technical & Quality Officer effective Jan 27, 2025, reporting to CEO.
- Ted Myles, COO & CFO, to remain through Mar 15, 2025, then serve as Senior Advisor until Sep 15, 2025.
- Myles receives 9 months base salary, 2024 bonus, prorated $202,400, and 9 months health benefits.
- Company expects first drug approval and commercial launch of apitegromab in 2025.
- Wyman previously led technical operations at Acceleron, which was sold to Merck for over $11B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000110465925007028/0001104659-25-007028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000110465925007028/tm254750d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-007028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer